Special Issue "Targeting Cancer Metastasis"
Deadline for manuscript submissions: closed (28 February 2021).
Interests: pharmacokinetics; natural compounds; anticancer agents; drug–drug interactions; cancer biomarkers
Special Issues and Collections in MDPI journals
Special Issue in Cancers: Hypoxia and Cancer: From Bench to Bedside
Tumor metastasis, one of crucial hallmarks of cancer, is the major cause of treatment failure in cancer patients, leading to 90% of cancer-related deaths. It is now widely recognized that metastatic lesions are distinct from the primary tumors which have been targeted traditionally. Thus, the development of novel therapeutic approaches to effectively prevent metastasis, as well as target metastatic lesions, is an unmet clinical need.
Metastasis is an inherently complex, heterogeneous and dynamic pathophysiological process that is highly dependent on the interaction of the tumor with the tumor microenvironment (TME). Multiple biological factors work synergistically to create pro-metastatic niches such as hypoxia, reprogrammed anaerobic glycolysis (Warburg effect), angiogenesis, vascular permeability, lymphatic vasculature, cancer stem cells, regulatory and suppressive immune cells, cancer-associated fibroblasts (CAFs), extracellular matrix, and tumor-derived exosomes (TDEs). Therefore, novel therapeutic strategies to normalize TME and clinical tests to precisely predict cancer metastasis can greatly improve survival outcome of cancer patients.
This Special Issue highlights new frontiers in the treatment of metastatic cancers, covering preclinical studies identifying novel druggable targets and discovering potent drug candidates, as well as clinical management of cancer metastasis in combination with predictive biomarkers to improve the outcome of cancer patients.
Dr. Lingzhi Wang
Dr. Qiang Jeremy Wen
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Cancer Therapeutics
- Warburg Effect
- Blood Vessel Disruption
- Tumor-derived Exosomes